Reference summary — not medical advice or a personal risk estimate.
Tamoxifen
Summary
Used to treat hormone-receptor-positive breast cancer; also classified by IARC as a cause of endometrial cancer.
Detail
Tamoxifen is a selective oestrogen-receptor modulator. IARC classified it as Group 1 with sufficient evidence for endometrial cancer. It is widely prescribed for hormone-receptor-positive breast cancer; patients taking it are typically monitored by their oncology team for endometrial changes. This entry exists because tamoxifen appears on the IARC Group 1 list; clinical decisions about whether to take it are between a patient and their clinician.
Regional relevance
global
Documented in these products
Presence in a product category doesn't imply the product causes cancer. Click each to see the source and context.
Sources
Consumer references
Third-party tools some readers use alongside primary evidence. Meyron doesn't endorse them; we link them because you'll otherwise hit them anyway.
- California Prop 65 list
State of California's list of chemicals known to cause cancer or reproductive harm.